Merck, known as MSD outside the United States and Canada, and Orion Corporation announced a global development and commercialization agreement for Orion’s investigational candidate ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer...READ MORE

Algernon Pharmaceuticals Inc., a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated a new CKD research program to investigate Repirinast as part of its drug repurposing program...READ MORE

In the medical device industry, scientific disciplines and engineering merge in the creation of innovations that benefit the health care system as well as society at large. Firms in this industry approach the diagnosis and treatment of ailments by providing a wide range of quality products suited to increasingly specialized needs...READ MORE

Pfizer Canada and Rethink Breast Cancer are excited to announce the recipients of the nearly $280,000 in grants for the implementation of innovative strategies aimed at measurably improving the quality of care for people living with metastatic breast cancer (MBC). In its second year, the collaboration between Pfizer Canada and Rethink is grounded in a commitment to prioritizing the voices and values of people living with MBC...READ MORE

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application (sBLA) expanding the labeling to include KRYSTEXXA® (pegloticase) injection co-administered with methotrexate, which will help more people with uncontrolled gout achieve a complete response to therapy. “Today’s approval for KRYSTEXXA with methotrexate is the culmination of more than five years of effort and demonstrates Horizon’s commitment to working together with the gout community to improve...READ MORE

Algernon Pharmaceuticals Inc., a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”). DMT is a known psychedelic compound that is part of the tryptamine family. The Company is currently working to complete the intravenous formulation that will be used in the Phase 1 DMT study and has retained the Centre for Human Drug Research...READ MORE

Clairvoyant Therapeutics, a Canadian biotech company, is pleased to announce it has initiated the first of 15 planned sites for CLARITY, the company’s Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder (formerly called alcoholism). CLARITY is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of 25 mg synthetic psilocybin in conjunction with Motivational Enhancement Therapy...READ MORE

BCIT is excited to celebrate the soft opening of the new Health Sciences Centre on the Burnaby Campus. With generous support from industry leaders and the philanthropic community, the INSPIRE Campaign raised $11.7 million towards the development of the state-of-the-art facility. The Province also provided an investment of $66.6-million into the project. The Health Sciences Centre, standing at four-storeys and 111,460 square-feet, is a critical hub for providing transformative, applied education to current and future generations of healthcare students in BC...READ MORE

Next Generation Manufacturing Canada (NGen) has announced $265k in co-funding, for a project led by Canadian biotechnology company Axolotl Biosciences in partnership with StarFish Medical to scale-up the production of BrainPrint bioink. BrainPrint can be used to print human brain tissue models as a tool for understanding neurodegenerative diseases and as a tool for drug screening...READ MORE

Life Sciences BC is pleased to announce the recipients of the 24th Annual Life Sciences BC Awards, presented by Farris. These awards recognize the achievements of individuals, companies, and organizations that have had success in advancing successful health innovations and contribute to BC’s life sciences ecosystem...READ MORE

Reporting directly to the R&D Manager, the Lead Scientist, Protein Engineering is an important member within the department and the company as a whole. The role is responsible to lead the development, optimization, and production scale up of proteins needed for IVD products on-time and on-budget:

You have rich experience of upstream and downstream protein engineering processes and experience with protein production under GMP requirement. You have strong planning skill to prioritize tasks and to adapt the changes when necessary. You have effective problem-solving skill to remove roadblocks and provide technical advice for the team members.

At Abdera Therapeutics, we are looking for curious and committed individuals who are ready for the opportunity to transform the way people living with cancer can be treated. We are relentless in our focus to offer new hope to families facing devastating diagnoses. We are in search of team members who work collaboratively with a diverse group of colleagues, respectfully engaging one another while collectively and inclusively tackling any challenges we may face. We are building an exciting and fast paced company passionate about discovering and developing tomorrow’s most innovative cancer therapies.